Christopher J. Hawkey
University of Nottingham
Publications 508
#1Amy Brenner (Lond: University of London)H-Index: 2
#2Adefemi O. Afolabi (University College Hospital, Ibadan)H-Index: 2
Last.Ian Roberts Mbbch (Lond: University of London)H-Index: 82
view all 18 authors...
Acute gastrointestinal (GI) bleeding is an important cause of mortality worldwide. Bleeding can occur from the upper or lower GI tract, with upper GI bleeding accounting for most cases. The main causes include peptic ulcer/erosive mucosal disease, oesophageal varices and malignancy. The case fatality rate is around 10% for upper GI bleeding and 3% for lower GI bleeding. Rebleeding affects 5–40% of patients and is associated with a four-fold increased risk of death. Tranexamic acid (TXA) decrease...
#1John A. Snowden (Royal Hallamshire Hospital)H-Index: 43
#2Christopher J. Hawkey (University of Nottingham)H-Index: 79
Last.Marrow TransplantationH-Index: 10
view all 21 authors...
Background Intestinal inflammation in Crohn’s disease (CD) is caused by mucosal immune system reactivity to luminal antigen and results in debilitating symptoms, reduced quality of life, impaired work productivity and significant health care costs. Not all patients respond to conventional and biologic therapies, with chronic inflammation ensuing. Although surgical resection may be required, disease frequently returns and surgery may not be an option, or may be declined. Case reports suggest pote...
#1Nicholas A. Kennedy (University of Exeter)H-Index: 26
#2Graham A. Heap (RD&E: Royal Devon and Exeter Hospital)H-Index: 1
Last.Stephen GoreH-Index: 1
view all 155 authors...
Summary Background Anti-TNF drugs are effective treatments for the management of Crohn's disease but treatment failure is common. We aimed to identify clinical and pharmacokinetic factors that predict primary non-response at week 14 after starting treatment, non-remission at week 54, and adverse events leading to drug withdrawal. Methods The personalised anti-TNF therapy in Crohn's disease study (PANTS) is a prospective observational UK-wide study. We enrolled anti-TNF-naive patients (aged ≥6 ye...
20 CitationsSource
#1Amy Lewis (QMUL: Queen Mary University of London)H-Index: 13
#2R Jeffrey (QMUL: Queen Mary University of London)
Last.James O. Lindsay (QMUL: Queen Mary University of London)H-Index: 37
view all 10 authors...
#1Diane J. StevensonH-Index: 3
Last.Christopher J. HawkeyH-Index: 79
view all 10 authors...
Introduction The Helicobacter Eradication Aspirin Trial (HEAT) is a multicentre, double blind, randomised controlled trial investigating whether Helicobacter pylori eradication reduces the incidence of hospitalisation for peptic ulcer bleeding [1]. Participants are subjects aged over 60, taking low dose aspirin for at least four months at the time of recruitment; all participants were recruited from primary care. H. pylori positive participants were randomised to receive one week active trial tr...
#1Raja Atreya (FAU: University of Erlangen-Nuremberg)H-Index: 20
#2Walter Reinisch (Medical University of Vienna)H-Index: 74
Last.Christopher J. Hawkey (University of Nottingham)H-Index: 79
view all 9 authors...
Abstract Background The Toll-like-receptor 9 (TLR-9) agonist cobitolimod (DIMS0150, Kappaproct®) is a promising therapeutic option for ulcerative colitis (UC) patients. Aims The objectives of this post-hoc analysis using the COLLECT study data was to investigate the clinical effects of cobitolimod using patient-reported-outcomes (PRO) defined endpoints. Methods Dual topical administration of cobitolimod was studied in a randomised, multicentre clinical trial named COLLECT in moderate-to-severe U...
2 CitationsSource
#1Isla S. Mackenzie (Dund.: University of Dundee)H-Index: 24
#2Ian Ford (Robertson Centre for Biostatistics)H-Index: 108
Last.Thomas M. MacDonald (Dund.: University of Dundee)H-Index: 61
view all 13 authors...
Background Allopurinol is licensed for the prevention of gout. In recent years, several studies have suggested that allopurinol may have beneficial effects on cardiovascular parameters. The ALL-HEART study is a large outcome trial designed to investigate whether allopurinol improves cardiovascular outcomes in patients with ischaemic heart disease[.1 It is a multicentre, controlled, prospective, randomised, open-label, blinded endpoint trial of allopurinol (up to 600 mg daily) versus no treatment...
#1Charlotte K. Brierley (Churchill Hospital)H-Index: 5
Last.John A. SnowdenH-Index: 43
view all 20 authors...
Background and Aims: Autologous haematopoietic stem cell transplantation [AHSCT] is a therapeutic option for patients with severe, treatment-refractory Crohn’s disease [CD]. The evidence base for AHSCT for CD is limited, with one randomised trial [ASTIC] suggesting benefit. The aim of this study was to evaluate safety and efficacy for patients undergoing AHSCT for CD in Europe, outside the ASTIC trial. Methods: We identified 99 patients in the European Society for Blood and Marrow Transplantatio...
6 CitationsSource
#1John A. Snowden (Royal Hallamshire Hospital)H-Index: 43
#2Julián PanésH-Index: 65
Last.Elena RicartH-Index: 29
view all 17 authors...
Despite the major recent progress in the treatment of Crohn’s disease [CD], there is a subset of patients in whom the disease runs an aggressive course with progressive tissue damage requiring early and repeated surgical management. Increasing evidence supports sustained and profound improvement in gastrointestinal parameters and quality of life following high-dose immunosuppressive therapy and autologous haematopoietic stem cell transplantation [AHSCT] compared to standard therapy in this conte...
15 CitationsSource
#1Benjamin Scally (Clinical Trial Service Unit)H-Index: 1
#2Jonathan Emberson (Medical Research Council)H-Index: 47
Last.Colin Baigent (Medical Research Council)H-Index: 66
view all 16 authors...
Summary Background Gastroprotectant drugs are used for the prevention and treatment of peptic ulcer disease and might reduce its associated complications, but reliable estimates of the effects of gastroprotectants in different clinical settings are scarce. We aimed to examine the effects of proton-pump inhibitors (PPIs), prostaglandin analogues, and histamine-2 receptor antagonists (H2RAs) in different clinical circumstances by doing meta-analyses of tabular data from all relevant unconfounded r...
19 CitationsSource